ALTUVIIIO™ approved by the US FDA: this positive event triggers an impairment reversal, which has a positive impact on the IFRS 2022 net income; no change in net income from operations (non-IFRS) – 02/24/2023 at 17:16

US FDA Approves ALTUIIIO

TM

once a week, a new class of factor VIII for the treatment of hemophilia A that confers significant protection against bleeding. This positive event triggers a reversal of impairment, which has a positive impact on the IFRS 2022 net income; no change in net income from operations (non-IFRS)

Filing of the 2022 Universal Registration Document, containing the Annual Financial Report, and of the American “Form 20-F”

Paris, February 24, 2023.

Sanofi announces that it has filed its 2022 Universal Registration Document containing the Annual Financial Report with the Autorité des marchés financiers (AMF) in France and its “Form 20-F” with the “Securities and Exchange Commission” (SEC) in UNITED STATES.

On February 22, 2023, the Food and Drug Administration (FDA) approved ALTUVIIIO

^TM

. This event confirms the significant increase in the value of the asset. This decision, which took place before the filing of the universal registration document and the “Form 20-F”, gave rise to an adjustment to the IFRS net income for the 2022 financial year, presented in the press release of February 3, 2023, corresponding the reversal of the impairment of intangible assets related to the Eloctate franchise for an amount of €2,154 million, in accordance with IAS36

Asset impairments

. These assets had been partially impaired in 2019. The adjustment is presented on the line

Impairment of intangibles

of the income statement. The net impact after tax represents a gain of 1,651 million euros. This change has no impact on cash flows. Following this adjustment, for the year 2022, the IFRS net income amounts to 8,371 million euros (compared to 6,720 million euros in the press release of February 3, 2023), the net earnings per share ( IFRS EPS) at 6.69 euros (compared to 5.37 euros in the press release of February 3, 2023), total equity at 75,152 million euros (compared to 73,512 million euros in the press release of February 3, 2023 ).

Net income from activities (non-IFRS indicator) for the 2022 financial year is unchanged, as is the amount of the dividend proposed by the Board of Directors on February 2, 2023.

Updated IFRS figures for 2022 financial statements

1

Unless otherwise indicated, the change in sales is expressed at constant exchange rates (CER) (see the definition Appendix 9 of the Press release dated February 3, 2023) (1) Commentary on the net income statement from activities, indicator not -IFRS, makes it possible to report on Sanofi’s economic performance (see definition in Appendix 9 of the Press Release dated February 3, 2023). The transition from IFRS net income to net income from operations is shown on page 62 of the US Form 20-F and on page 142 of the Universal Registration Document; (2) Free Cash Flow is a non-IFRS indicator (see definition in Appendix 9 of the Press Release dated February 3, 2023).

The documents can be consulted on the company’s website: www.sanofi.com/fr/investors/rapports-et-publications/rapports-financiers-et-rse.

The Universal Registration Document is also available on the AMF website (www.amf-france.org) and the “Form 20-F” on the SEC website (www.sec.gov). A printed version of these documents containing the audited financial statements can be obtained on request and free of charge.

About Sanofi


We are an innovative, global health company driven by one purpose: to pursue the miracles of science to improve people’s lives. Our teams, present in a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media relations

Sandrine Guendoul

| + 33 6 25 09 14 25 |

[email protected]

Victor Rouault

| + 33 6 70 93 71 40 |

[email protected]

Evan Berland

| +1 215 432 0234 | [email protected]

Kate Conway

| + 1 508 364 4931 |

[email protected]

Investor Relations

Eva Schaefer-Jansen

| + 33 7 86 80 56 39 | [email protected]

Arnaud Delépine

| + 33 6 73 69 36 93 | [email protected]

Corentine Driancourt

| + 33 6 40 56 92 21 | [email protected]

Felix Lauscher

| + 1 908 612 7239 | [email protected]

Tarik Elgoutni |

+ 1 617 710 3587 | tarik.e [email protected]

Nathalie Pham

| + 33 7 85 93 30 17 | [email protected]

1. Updated from the results press release of February 3, 2023
   

Attachment